Liver cancer is classified into stages based on tumor size, whether cancer has reached nearby lymph nodes, and whether it has spread to other organs. Most staging systems range from Stage I (a small, contained tumor) to Stage IV (cancer that has spread beyond the liver). The stage at diagnosis is the single biggest factor in determining treatment options and survival outlook.
Why Liver Cancer Staging Is Complex
Unlike many cancers, liver cancer staging doesn’t just look at the tumor itself. It also considers how well your liver is functioning, because most people with liver cancer also have underlying liver disease like cirrhosis or chronic hepatitis. A tumor that might be surgically removable in a healthy liver could be untreatable in a liver that’s already failing. This is why doctors use multiple staging systems, sometimes simultaneously, to get the full picture.
The two most widely used systems are the TNM system (which focuses on the tumor) and the BCLC system (which factors in liver health and overall physical condition). Your care team may reference both.
The TNM Staging System
The TNM system, maintained by the American Joint Committee on Cancer, assigns a stage based on three factors: tumor characteristics (T), lymph node involvement (N), and distant metastasis (M). Here’s what each stage looks like in practice.
Stage I: A single tumor 2 centimeters or smaller that hasn’t grown into any blood vessels. There’s no lymph node involvement and no spread to distant organs. This is the most contained form of liver cancer.
Stage II: The tumor is either a single small tumor (2 cm or less) that has started growing into blood vessels, multiple tumors confined to one side of the liver that are all 2 cm or smaller, or a single tumor larger than 2 cm that hasn’t invaded blood vessels. Cancer still hasn’t reached lymph nodes or distant sites.
Stage III: This stage covers a wider range of scenarios. The tumor may be a single mass larger than 2 cm that has grown into blood vessels, or there may be multiple tumors of varying sizes in one lobe of the liver. The key distinction from Stage II is that cancer may have also spread to nearby lymph nodes, though it hasn’t traveled to distant organs.
Stage IVA: Multiple tumors have spread across more than one lobe of the liver, or the cancer has invaded a major branch of the portal vein or hepatic vein (the liver’s primary blood supply routes). This represents locally advanced disease.
Stage IVB: Cancer has spread to distant parts of the body. The lungs are the most common destination, found in 18 to 60 percent of cases with extrahepatic spread. Abdominal lymph nodes and bones are the next most frequent sites. Bone metastases from liver cancer are almost always lytic, meaning they break down bone tissue rather than building it up.
The BCLC Staging System
The Barcelona Clinic Liver Cancer system takes a broader view. Rather than focusing purely on tumor anatomy, it incorporates how well your liver is working and your general physical ability to function day to day. It uses five stages labeled 0 through D.
Stage 0 (very early): A single small tumor in a liver that’s still functioning well. The person feels healthy and active. This is the ideal window for curative treatment.
Stage A (early): Still potentially curable. The tumor burden is limited, and liver function remains adequate to tolerate treatment like surgery or localized tumor destruction.
Stage B (intermediate): Multiple tumors are present, but they’re still confined to the liver. The person’s overall health is reasonable, though the extent of disease rules out surgery.
Stage C (advanced): Cancer may have invaded blood vessels or spread to lymph nodes. The person’s physical function has started to decline. Surgery is no longer safe or effective. This stage is considered locally advanced.
Stage D (end-stage): The liver is severely damaged, physical health is poor, or cancer has spread to distant organs. Treatment at this point focuses on comfort and quality of life rather than controlling the tumor.
How Liver Function Shapes Your Stage
Doctors assess liver health using a scoring tool called the Child-Pugh score, which measures five things: bilirubin levels in your blood (a marker of how well your liver processes waste), albumin levels (a protein your liver makes), how quickly your blood clots, whether fluid is building up in your abdomen, and whether liver disease is affecting your brain function.
These five measures produce a score that falls into one of three classes. Class A means your liver is still working normally. Class B indicates moderate damage. Class C means severe or advanced liver damage. Someone with a Class C liver and a small tumor may actually have fewer treatment options than someone with a Class A liver and a larger tumor, because the liver itself can’t withstand aggressive treatment.
Symptoms at Different Stages
Most people with early-stage liver cancer have no symptoms at all. The liver is large enough that a small tumor doesn’t disrupt its function, and there are no nerve endings inside the organ to signal pain. This is why liver cancer is often caught during routine screening of people already known to have cirrhosis or hepatitis, or found incidentally on imaging done for another reason.
Symptoms typically emerge as the disease progresses. These can include unexplained weight loss, loss of appetite, pain in the upper right abdomen, nausea and vomiting, general fatigue, and abdominal swelling from fluid buildup. Jaundice (yellowing of the skin and whites of the eyes) and pale, chalky stools signal that the tumor is interfering with bile flow. Some people develop visible enlarged veins on the abdomen, fever, or unusual bruising and bleeding. By the time symptoms appear, the cancer is often at an intermediate or advanced stage.
How Staging Is Determined
Liver cancer staging relies heavily on imaging. Multiphase CT scans and MRI are the standard tools, and they work by exploiting a quirk of liver cancer biology: malignant tumors in the liver develop their own abnormal blood supply. On a contrast-enhanced scan, cancerous nodules light up brightly during the arterial phase (when contrast dye first floods in) and then “wash out” faster than surrounding tissue. This pattern is distinctive enough to diagnose liver cancer without a biopsy in many cases.
A standardized reporting system called LI-RADS helps radiologists categorize suspicious liver lesions consistently. The same imaging also determines the tumor’s T stage by showing its size, whether there are multiple tumors, which lobes are involved, and whether cancer has grown into blood vessels.
Survival Rates by Stage
Five-year survival rates vary dramatically depending on how far the cancer has spread at diagnosis. For localized liver cancer (confined to the liver), the five-year relative survival rate is 37.4 percent. Once cancer has spread to regional lymph nodes, that drops to 13.4 percent. For distant metastatic disease, the five-year survival rate is 3.6 percent. These figures come from the National Cancer Institute’s SEER database and reflect cases diagnosed between 2016 and 2022.
These numbers represent averages across all patients and all treatments. Individual outcomes depend on tumor specifics, liver function, overall health, and which treatments are available. Notably, treatment options have expanded in recent years. Immunotherapy combined with targeted therapy has become a standard approach for advanced disease, and some patients who respond well to these drugs have been able to undergo surgery that wouldn’t have been possible at their original diagnosis. A recent study found that patients with advanced liver cancer involving major blood vessel invasion who responded to immunotherapy and then had surgery had significantly longer periods before their treatment stopped working, compared to those who stayed on drug therapy alone.
Treatment Approaches by Stage Group
Early-stage disease (BCLC 0 and A) offers the best chance for cure. Options include surgical removal of the tumor, liver transplant, or ablation, which destroys the tumor in place using heat or other energy. These approaches aim to eliminate the cancer entirely.
Intermediate-stage disease (BCLC B) is typically treated with procedures that target tumors directly through blood vessels, delivering chemotherapy or radiation beads straight to the tumor while sparing the rest of the liver.
Advanced-stage disease (BCLC C) relies on systemic therapies that circulate throughout the body. Immunotherapy-based combinations have become the frontline approach, replacing older targeted drugs that were the standard for over a decade.
End-stage disease (BCLC D) shifts the focus to symptom management and supportive care. The liver is too compromised, or the person’s health too fragile, for treatments aimed at the tumor itself.